These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15669206)

  • 1. [New aspects in the management of renal osteodystrophy].
    Matuszkiewicz-Rowińska J
    Pol Arch Med Wewn; 2004 Oct; 112 Spec No():89-97. PubMed ID: 15669206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure].
    Hoshino J; Ubara Y; Takaichi K
    Clin Calcium; 2004 May; 14(5):731-7. PubMed ID: 15577034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Slowing the progression of vascular calcification in hemodialysis.
    Chertow GM
    J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S310-4. PubMed ID: 12939387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving phosphate-binder therapy as a way forward.
    Hutchison AJ
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the treatment of chronic kidney disease-mineral and bone disorder.
    Bover J; Farré N; Andrés E; Canal C; Olaya MT; Alonso M; Quílez B; Ballarín J
    J Ren Care; 2009 Mar; 35 Suppl 1():19-27. PubMed ID: 19222727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
    Ogata H; Koiwa F; Shishido K; Kinugasa E
    Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphate binders and management of hyperphosphataemia in end-stage renal disease.
    Savica V; Calò LA; Monardo P; Santoro D; Bellinghieri G
    Nephrol Dial Transplant; 2006 Aug; 21(8):2065-8. PubMed ID: 16766546
    [No Abstract]   [Full Text] [Related]  

  • 8. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats.
    Katsumata K; Kusano K; Hirata M; Tsunemi K; Nagano N; Burke SK; Fukushima N
    Kidney Int; 2003 Aug; 64(2):441-50. PubMed ID: 12846739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventive measures and new pharmacological approaches of calcium and phosphate disorders.
    Cozzolino M; Galassi A; Pasho S; Fallabrino G; Gallieni M; Brancaccio D
    Contrib Nephrol; 2008; 161():234-239. PubMed ID: 18451682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease.
    Lindberg JS
    Kidney Int Suppl; 2005 Jun; (95):S33-6. PubMed ID: 15882311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial.
    Chertow GM; Dillon MA; Amin N; Burke SK
    J Ren Nutr; 2000 Jul; 10(3):125-32. PubMed ID: 10921533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of treatment of renal osteodystrophy on bone histology.
    Malluche HH; Mawad H; Monier-Faugere MC
    Clin J Am Soc Nephrol; 2008 Nov; 3 Suppl 3(Suppl 3):S157-63. PubMed ID: 18988701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of coronary artery calcification in ESRD patients].
    Yokoyama K
    Clin Calcium; 2004 Jun; 14(6):109-15. PubMed ID: 15577064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prophylaxis and treatment of adynamic bone].
    Ogata H; Yamamoto M; Taguchi S
    Clin Calcium; 2004 Sep; 14(9):34-9. PubMed ID: 15577107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Front line of management of hyperphosphatemia in hemodialysis patients].
    Yumita S
    Clin Calcium; 2004 May; 14(5):771-7. PubMed ID: 15577041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis.
    Huybrechts KF; Caro JJ; Wilson DA; O'Brien JA
    Value Health; 2005; 8(5):549-61. PubMed ID: 16176493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of new phosphate binders for chronic renal failure.
    Loghman-Adham M
    Drug Saf; 2003; 26(15):1093-115. PubMed ID: 14640773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management of secondary hyperparathyroidism].
    Cunningham J
    Clin Calcium; 2005 Sep; 15 Suppl 1():217-24. PubMed ID: 16279027
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
    Pai AB; Smeeding JE; Brook RA
    Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperphosphataemia in renal failure: causes, consequences and current management.
    Albaaj F; Hutchison A
    Drugs; 2003; 63(6):577-96. PubMed ID: 12656655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.